12-hydroxy-5-8-10-14-eicosatetraenoic-acid and carprofen

12-hydroxy-5-8-10-14-eicosatetraenoic-acid has been researched along with carprofen* in 1 studies

Other Studies

1 other study(ies) available for 12-hydroxy-5-8-10-14-eicosatetraenoic-acid and carprofen

ArticleYear
Evaluation of carprofen in calves using a tissue cage model of inflammation.
    The British veterinary journal, 1996, Volume: 152, Issue:2

    The arylpropionate anti-inflammatory drug, carprofen, was administered intravenously as the racemate at a dose rate of 0.7 mg kg-1 body weight to six Friesian bull calves aged 16-17 weeks. Anti-inflammatory and pharmacokinetic properties were investigated using a tissue cage model of inflammation based on intracaveal injection of the mild irritant, carrageenin. Carprofen displayed enantioselective pharmacokinetics, with the R(-) enantiomer predominating in plasma at all measuring times. Elimination half-life and mean residence time were shorter and volume of distribution and clearance were greater for the S(+) than for the R(-) enantiomer. Penetration of both enantiomers into transudate (non-stimulated tissue cage) was poor but penetration into exudate (carrageenin-stimulated tissue cage) was good. Carprofen failed to reduce exudate concentration of prostaglandin E2 and the reductions in 12-hydroxyeicosatetraenoic acid were non-significant at most sampling times. The long elimination half-life of both R(-) and S(+) carprofen enantiomers and their ready penetration into and slow clearance from inflammatory exudate indicate that the drug is likely to have a long duration of action in calves. The mechanism of action is unknown but it is unlikely to involve inhibition of either cyclooxygenase or 12-lipoxygenase.

    Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; Acute Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Carrageenan; Cattle; Cattle Diseases; Cross-Over Studies; Dinoprostone; Exudates and Transudates; Hydroxyeicosatetraenoic Acids; Inflammation; Male; Proteins; Time Factors; Zymosan

1996